Biomedical subjects

S F Cooper

Publications and source records attributed to S F Cooper.

33 records · Page 2Linked to original sources

PubMed1979

Determination of loxapine in human plasma and urine and identification of three urinary metabolites.

1. A g.l.c. method for quantitative determination of loxapine (2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine), in human plasma and urine is described. 2. Preliminary pharmacokinetic data on plasma concn of loxapine over 12 h from five psychiatric patients who received a total average dose of 80 mg of loxapine succinate per day orally for twelve weeks are presented. 3. In addition to unchanged loxapine, three urinary metabolic products, namely aromatic ring-hydroxy loxapine, desmethyl loxapine and loxapine-N-oxide, were identified using g.l.c.--mass spectrometry.

Adult↗

PubMed1977

The children of psychiatric patients: clinical findings.

Findings are presented on 42 children of school age, the offspring of 26 adult psychiatric patients. Psychiatric disorder was found in 19 (45 per cent) of the children, compared with 12 (26 per cent) of 47 children from a control group of families. Families with disturbed children differed from the remaining families in the following ways: presence of frank marital discord, the diagnosis of personality disorder in the parents, the inability of the father to tolerate angry situations, and the presence of siblings of under 9 years of age. Six months later 9 of the 19 children had improved considerably. In almost every family this was associated with improvement in the condition of the parents. It is suggested that the psychiatric disorder of these children is reactive to the presence of emotional turmoil in the families.

Adolescent↗

PubMed1975

Penfluridol steady-state kinetics in psychiatric patients.

Twenty-two hospitalized schizophrenic patients, participating in a large-scale phase II double-blind dose-effect study (30, 60, and 120 mg weekly) of penfluridol, a new diphenylbutylpiperidine neuroleptic, were maintained on a regular dosage regimen for 13 wk. Several blood samples were taken during the last dosage interval. Results show that the peak concentration develops within 12 hr after the last dose. A rapid decline, probably due to tissue re-equilibration, then occurs and is followed by a much slower falloff. Detectable concentrations 168 hr after administration are consistent with the long duration of action of penfluridol. Statistically significant differences between doses were found in the analysis of variance of plasma concentrations at all sampling times and in mean steady-state plasm concentrations. Wide differences in plasma concentrations were noted in patients receiving the same absolute dose, but a good relationship was defined between mean steady-state concentration and the dose expressed as mg per either kg of body weight or square meter of body surface area.

Administration, Oral↗

PubMed1975

Gas-liquid chromatographic determination of penfluridol in plasma. A new specific technique.

Penfluridol is a new long-acting neuroleptic drug, first shown by Janssen et al. (1970) and later proved by numerous clinical investigations. The plasma level data are in agreement with these findings since penfluridol is measurable in plasma of the patients 7 days after the oral dose of 120 mg/week. In summary, we have provided for the first time a rapid, accurate and precise gas-chromatographic method for measurement of penfluridol in the plasma of schizophrenic patients.

Chromatography, Gas↗

PubMed1975